Tang Ren-Guang, Yuan Xi-Hua, Tang Tian-Tian, Tang Xi-Qiang, Hang Yan-Qing, Qin Hou-Ji, Chen Hong-Ming, Fang Wen-Zhu, Long Xian-Ke
Department of Clinical Laboratory Center, The Affiliated Hospital of Medical College of Youjiang for Nationality, Baise 533000, China.
Zhonghua Yu Fang Yi Xue Za Zhi. 2007 Jun;41 Suppl:35-8.
To study the changes of serum interleukin-2 (IL-2), interleukin-8 (IL-8) and immunoglobulin (IgG, IgA, IgM) in patients with esophageal cancer, and to probe the relationship between the levels of IL-2, IL-8, IgG, IgA and IgM and the progress of cancer.
The serum levels of IL-2 and IL-8 were detected by enzyme-linked immunosorbent assay for 72 case of primary esophageal cancer, 68 advanced esophageal cancer and 120 healthy controls, and the level of immunoglobulin (IgG, IgA, IgM) in patients with esophageal cancer was dynamically observed.
The IL-2 level in patients with early esophageal cancer [(1.69 +/- 0.53) ng/ml] or late esophageal cancer [(1.11 +/- 0.60) ng/ml] was lower than the control group [(2.78 +/- 0.51) ng/ml] (P < 0.01), the late esophageal cancer group was lower than early esophageal cancer group (P < 0.05). The level of IL-8 in patients with early esophageal cancer [(85.48 +/- 6.14) ng/L] or late esophageal cancer [(121.41 +/- 6.22) ng/L] was much higher than the control group [(54.48 +/- 12.20) ng/L] (P < 0.01), the late esophageal cancer group was much higher than early esophageal cancer group (P < 0.01); There was correlation between the levels of IL-2 and IL-8 and the worsen-extent of the tumour in patients with early esophageal cancer or late esophageal cancer. But the level of IgG [(12.23 +/- 2.50) g/L], IgM [(1.60 +/- 0.80) g/L] in the patients with esophageal cancer compared with the level of IgG [(11.65 +/- 3.70) g/L], IgM [(1.46 +/- 0.71) g/L] in the health control group have no significant difference (P > 0.05), the level of IgA [(3.50 +/- 1.10) g/L] in patients with esophageal cancer Compared with the control group [(1.88 +/- 1.08) g/L] has significant difference (P < 0.01), and along with the worsen-extent of the tumor in patients the level of IgA has the increased tendency.
The IL-8 might accelerate the pathogenesis of esophageal cancer, and the IL-2 might restrain. The positive correlation between the level of IgA and the patients with esophageal cancer is observed in this study; the immune maladjustment of IL-2, IL-8 and IgA might be correlative to esophageal cancer, and the IL-2, IL-8 and IgA levels might be an available index for the severity of esophageal cancer, Which may be of some help for clinic practitioners to judge the progress, curative effect and prognosis of the cancer.
研究食管癌患者血清白细胞介素-2(IL-2)、白细胞介素-8(IL-8)及免疫球蛋白(IgG、IgA、IgM)的变化,探讨IL-2、IL-8、IgG、IgA及IgM水平与癌症进展的关系。
采用酶联免疫吸附试验检测72例原发性食管癌患者、68例进展期食管癌患者及120例健康对照者血清中IL-2和IL-8水平,并动态观察食管癌患者免疫球蛋白(IgG、IgA、IgM)水平。
早期食管癌患者[(1.69±0.53) ng/ml]及晚期食管癌患者[(1.11±0.60) ng/ml]的IL-2水平低于对照组[(2.78±0.51) ng/ml](P<0.01),晚期食管癌组低于早期食管癌组(P<0.05)。早期食管癌患者[(85.48±6.14) ng/L]及晚期食管癌患者[(121.41±6.22) ng/L]的IL-8水平显著高于对照组[(54.48±12.20) ng/L](P<0.01),晚期食管癌组高于早期食管癌组(P<0.01);早期或晚期食管癌患者IL-2和IL-8水平与肿瘤恶化程度相关。但食管癌患者IgG[(12.23±2.50) g/L]、IgM[(1.60±0.80) g/L]水平与健康对照组IgG[(11.65±3.70) g/L]、IgM[(1.46±0.71) g/L]水平相比,差异无统计学意义(P>0.05),食管癌患者IgA[(3.50±1.10) g/L]水平与对照组[(1.88±1.08) g/L]相比,差异有统计学意义(P<0.01),且随患者肿瘤恶化程度IgA水平有升高趋势。
IL-8可能加速食管癌发病机制,而IL-2可能起抑制作用。本研究观察到IgA水平与食管癌患者呈正相关;IL-2、IL-8及IgA免疫失调可能与食管癌相关,IL-2、IL-8及IgA水平可能是评估食管癌严重程度的有用指标,这可能有助于临床医生判断癌症的进展、疗效及预后。